highlighted the CyberKnife System as an effective and time efficient treatment option for brain stem metastases. Additionally, in October, we announced the publication of the Accuray sponsored ...

Accuray Incorporated (NASDAQ ... and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary ...

Q2 2025 Earnings Call Transcript February 5, 2025 Accuray Incorporated beats earnings expectations. Reported EPS is $0.02, expectations were $-0.01. Operator: Good day, and welcome to the Accuray ...

And also, within those markets, a breakthrough high-end premium technology like CyberKnife is also very attractive to establish the Accuray technology brand. So, it's not pricing, it is technology.

Accuray Inc (ARAY) reports an 8% revenue increase, driven by robust product sales and significant growth in China and Japan.

For example, in December, the international Journal of Cancer, highlighted the CyberKnife System as an effective and time efficient treatment option for brain stem metastases. Additionally, in October ...

Accuray had a negative return on equity of ... and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the ...